<rdf:RDF
    xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
    xmlns:j.0="http://www.ddmore.org/ontologies/webannotationtool#"
    xmlns:j.1="http://www.pharmml.org/ontology/"
    xmlns:j.2="http://www.pharmml.org/2013/10/PharmMLMetadata#" > 
  <rdf:Description rdf:about="http://repository.ddmore.eu/model/DDMODEL00000218">
    <rdf:type rdf:resource="http://www.pharmml.org/ontology/PHARMMLO_0000001"/>
    <j.2:model-tasks-in-scope rdf:resource="http://www.ddmore.org/ontologies/ontology/pkpd-ontology#pkpd_0006001"/>
    <j.2:model-research-stage rdf:resource="http://www.ddmore.org/ontologies/ontology/pkpd-ontology#pkpd_0006010"/>
    <j.0:model-implementation-conforms-to-literature-controlled rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Yes</j.0:model-implementation-conforms-to-literature-controlled>
    <j.2:model-has-description rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Oncology, specifically Phase II/1b to Phase III drug development phases. The developed modelling framework links change in tumour size during treatment to survival probability in metastatic ovarian cancer. In addition the appearance of new lesions and their relationship to survival and disease characteristics has been captured.</j.2:model-has-description>
    <j.2:model-modelling-question rdf:resource="http://www.ddmore.org/ontologies/ontology/pkpd-ontology#pkpd_0006037"/>
    <j.0:model-origin-of-code-in-literature-controlled rdf:datatype="http://www.w3.org/2001/XMLSchema#string">No</j.0:model-origin-of-code-in-literature-controlled>
    <j.0:model-implementation-source-discrepancies-freetext rdf:datatype="http://www.w3.org/2001/XMLSchema#string">None apart from using simulated patient data</j.0:model-implementation-source-discrepancies-freetext>
    <j.2:model-field-purpose rdf:resource="http://www.ddmore.org/ontologies/ontology/pkpd-ontology#pkpd_0000036"/>
  </rdf:Description>
</rdf:RDF>
